OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Molecular Hepatology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	251
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease	176
Global incidence and prevalence of nonalcoholic fatty liver disease	157
MAFLD: How is it different from NAFLD?	128
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	128
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach	100
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis	94
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future	85
Recent updates on the management of autoimmune hepatitis	81
Current understanding of primary biliary cholangitis	78
<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis	74
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	66
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region	64
Non-alcoholic fatty liver disease: Definition and subtypes	60
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	60
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis	57
KASL clinical practice guidelines for management of chronic hepatitis B	56
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease	54
Recent advances in nonalcoholic fatty liver disease metabolomics	50
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	50
RNA interference as a novel treatment strategy for chronic hepatitis B infection	44
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name	44
Changes in the epidemiology and management of bacterial infections in cirrhosis	42
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	40
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective	40

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry	38
The management of post-transplantation recurrence of hepatocellular carcinoma	36
The latest global burden of liver cancer: A past and present threat	36
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective	34
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis	33
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity	32
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease	32
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases	32
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	32
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus	32
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan	32